Safety and efficacy of topical formulations containing 0·5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study

Br J Dermatol. 2020 Jan;182(1):229-231. doi: 10.1111/bjd.18234. Epub 2019 Sep 1.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Axilla
  • Double-Blind Method
  • Glycopyrrolate* / adverse effects
  • Humans
  • Hyperhidrosis* / drug therapy
  • Treatment Outcome

Substances

  • Glycopyrrolate